Thymosin Alpha 1 10mg (10 vials/kit): Immunomodulatory Thymic Peptide for Preclinical Research

Thymosin Alpha 1 ($\text{T}\alpha1$) is an endogenous, naturally occurring 28-amino-acid peptide ($\text{Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH}$) originally isolated from bovine thymic tissue (Thymosin Fraction 5). As a primary regulator of adaptive and innate immune function, Thymosin Alpha 1 modulates intracellular signaling downstream of Toll-like receptors (TLR2, TLR7, and TLR9) in dendritic cells and myeloid cells. Sourcing Thymosin Alpha 1 10mg (10 vials/kit) equips immunologists, oncologists, and preclinical researchers with a high-purity analytical reagent engineered to investigate T-cell differentiation, natural killer ($\text{NK}$) cell activation, cytokine signaling dynamics, and host-pathogen interaction models.

In cellular and molecular immunology, Thymosin Alpha 1 acts as a potent immunomodulating agent rather than a direct immunosuppressive or immunostimulatory compound. By interacting with early-stage hematopoietic progenitor cells and mature lymphocytes, $\text{T}\alpha1$ promotes the maturation of T-helper ($\text{CD4}^+$) and cytotoxic T-lymphocytes ($\text{CD8}^+$) while stimulating nuclear factor kappa B ($\text{NF-}\kappa\text{B}$) and mitogen-activated protein kinase ($\text{MAPK}$) pathways. This dual activation upregulates key Th1 cytokines—including interferon-gamma ($\text{IFN-}\gamma$) and interleukin-2 ($\text{IL-2}$)—while suppressing excessive pro-inflammatory tissue damage through regulatory T-cell ($\text{T}_\text{reg}$) modulation.

Maintaining chemical stability and sequence integrity is critical for quantitative receptor-binding assays and cell culture protocols. The Thymosin Alpha 1 10mg (10 vials/kit) configuration delivers a total yield of 100mg active peptide material (10mg per vial) distributed across ten individual USP Type I borosilicate glass vials. Freeze-dried under sterile vacuum conditions, each vial contains a uniform, highly stable lyophilized powder cake. This multi-vial kit structure allows research personnel to reconstitute only the active working volume required for immediate experimental runs, keeping remaining kit stock preserved in deep freeze stasis to eliminate structural loss caused by repeated freeze-thaw cycles.

Immunomodulatory Signaling, T-Cell Kinetics, and Technical Specifications

The primary scientific value of Thymosin Alpha 1 10mg (10 vials/kit) stems from its central regulatory role across innate and adaptive immune response cascades:

• Toll-Like Receptor Activation (TLR2/7/9): Triggers intracellular myeloid differentiation primary response 88 ($\text{MyD88}$) pathways in dendritic cells, enhancing antigen presentation capacity and major histocompatibility complex ($\text{MHC-I}$) expression.

• T-Lymphocyte & NK Cell Maturation: Promotes the differentiation of immature thymocytes into functional $\text{CD4}^+$ and $\text{CD8}^+$ T-cells, while increasing natural killer ($\text{NK}$) cell lytic activity.

• Balanced Cytokine Expression: Stimulates Th1-type cytokine production ($\text{IFN-}\gamma$, $\text{IL-2}$, $\text{IL-12}$) while modulating Th2 pathways to restore immune homeostasis in immunocompromised models.

• Antiviral & Antitumor Research Utility: Widely studied in preclinical models to examine host defense enhancement against chronic viral replication and tumor immune evasion mechanisms.

• Ultra-High Chemical Purity ($\ge$99.0%): Manufactured via automated Solid-Phase Peptide Synthesis ($\text{SPPS}$) and purified using preparative High-Performance Liquid Chromatography ($\text{HPLC}$) to ensure complete removal of truncated fragments and organic impurities.

Reconstitution Guidelines, Laboratory Storage Standards, and Quality Protocols

Achieving reproducible, publication-grade results when working with Thymosin Alpha 1 10mg (10 vials/kit) requires strict adherence to standardized laboratory preparation and climate-controlled storage protocols.

Perform all reconstitution procedures inside a certified Class II Biosafety Cabinet:

1. Temperature Equilibration: Allow the frozen Thymosin Alpha 1 vial to adjust to ambient room temperature prior to solvent introduction to eliminate moisture condensation inside the glass container.

2. Septum Sanitization: Remove the protective plastic flip-cap and thoroughly wipe the synthetic rubber stopper with a fresh 70% isopropyl alcohol pad. Allow the surface to dry completely.

3. Slow Diluent Addition: Using a sterile syringe equipped with a fine-gauge needle, draw the required volume of Bacteriostatic Water (0.9% benzyl alcohol), Sterile Normal Saline (0.9% NaCl), or Phosphate-Buffered Saline (PBS). Direct the liquid stream against the inner glass wall so it trickles slowly over the lyophilized cake.

4. Gentle Hydration: Allow the diluent to fully hydrate the powder cake for 2 minutes. Gently roll the vial between your palms or swirl in smooth circular motions until clear. Never vortex or shake vigorously, as high-shear agitation can shear peptide bonds and induce protein foaming.

5. Micro-Aliquot Strategy: For multi-week testing protocols, divide reconstituted liquid into sterile, single-use microcentrifuge tubes under aseptic conditions to prevent atmospheric oxidation and eliminate repeated freeze-thaw cycles.

Batch Quality Documentation & Traceability: Every production lot of Thymosin Alpha 1 10mg (10 vials/kit) undergoes third-party analytical testing. High-Performance Liquid Chromatography (HPLC) chromatograms confirm component purity exceeding 99.0%, while Electrospray Ionization Mass Spectrometry (ESI-MS) confirms precise theoretical molecular mass. Each shipment includes a batch-specific Certificate of Analysis (COA) documenting chemical purity, residual solvent analysis, heavy metal screens, and bacterial endotoxin levels (<0.05 EU/mg) to satisfy institutional compliance requirements.

Strict Regulatory & Research Compliance Statement: Thymosin Alpha 1 10mg (10 vials/kit) is produced, packaged, and distributed exclusively for in vitro laboratory research, academic experimentation, chemical synthesis, and preclinical research. Thymosin Alpha 1 10mg (10 vials/kit) is strictly not intended, formulated, or approved for human or animal consumption, therapeutic medical treatment, clinical diagnostic work, or cosmetic applications. All handling must be conducted by certified research personnel operating within equipped laboratory facilities in compliance with OSHA workplace safety regulations and institutional biosafety protocols.